Conley Chee's most recent trade in Syros Pharmaceuticals Inc. was a trade of 134,797 Common Stock done at an average price of $0.2 . Disclosure was reported to the exchange on Nov. 18, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Syros Pharmaceuticals Inc. | Conley Chee | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.20 per share. | 18 Nov 2024 | 134,797 | 0 (0%) | 0% | 0.2 | 26,932 | Common Stock |
| Syros Pharmaceuticals Inc. | Conley Chee | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 17,000 | 0 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Conley Chee | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 17,000 | 139,504 (0%) | 0% | - | Common Stock | |
| Syros Pharmaceuticals Inc. | Conley Chee | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.09 per share. | 31 Oct 2024 | 8,707 | 130,797 (0%) | 0% | 2.1 | 18,198 | Common Stock |
| Syros Pharmaceuticals Inc. | Conley Chee | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.71 per share. | 10 Sep 2024 | 50,000 | 122,504 (0%) | 0% | 1.7 | 85,420 | Common Stock |
| Syros Pharmaceuticals Inc. | Conley Chee | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.51 per share. | 10 Sep 2024 | 50,000 | 72,504 (0%) | 0% | 1.5 | 75,260 | Common Stock |
| Syros Pharmaceuticals Inc. | Conley Chee | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 11,666 | 23,334 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Conley Chee | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 11,666 | 26,004 (0%) | 0% | - | Common Stock | |
| Syros Pharmaceuticals Inc. | Conley Chee | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.12 per share. | 31 Mar 2024 | 3,500 | 22,504 (0%) | 0% | 5.1 | 17,920 | Common Stock |
| Syros Pharmaceuticals Inc. | Conley Chee | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Conley Chee | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 14,338 (0%) | 0% | - | Common Stock | |
| Syros Pharmaceuticals Inc. | Conley Chee | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2023 | 86,000 | 86,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Conley Chee | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 6,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Conley Chee | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 2,000 (0%) | 0% | - | Common Stock | |
| Syros Pharmaceuticals Inc. | Conley Chee | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.58 per share. | 31 Mar 2023 | 658 | 1,342 (0%) | 0% | 2.6 | 1,698 | Common Stock |
| Syros Pharmaceuticals Inc. | Conley Chee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 35,000 | 35,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Conley Chee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 44,500 | 44,500 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Conley Chee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 34,000 | 34,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Conley Chee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Conley Chee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 80,000 | 80,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Conley Chee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Sep 2021 | 360,000 | 360,000 | - | - | Stock Option (right to buy) |